Abstract: The present invention relates to a vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection. The vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection according to the present invention comprises spike and ORF3a or nucleocapsid as an antigen against SARS-CoV-2. The vaccine composition has a significant effect of inducing antibody immune responses and T-cell immune responses by a plurality of co-expressed antigens compared to those comprising one antigen, and thus can be variously used in the field of prevention of severe acute respiratory syndrome coronavirus 2 infection.

Abstract: The present disclosure relates to a vaccine composition for preventing or treating infectious diseases caused by severe fever with thrombocytopenia syndrome (SFTS) virus.

Abstract: The present invention provides a DNA vaccine composition for preventing and treating herpes zoster, containing: at least one type of plasmid containing the insertion site of a varicella-zoster virus (VZV)-derived gene encoding a VZV protein; and other pharmaceutically acceptable ingredients. The plasmid contains a plurality of plasmids containing the insertion site of heterologous genes which are different from each other. The plasmid contains: a first plasmid containing the insertion site of a first gene encoding IE-62 protein (SEQ ID NO: 1); a second plasmid containing the insertion site of a second gene encoding IE-63 protein (SEQ ID NO: 2); and a third plasmid containing the insertion site of a third gene encoding gE protein (SEQ ID NO: 3).